胰腺癌-南通抗癌协会.ppt

* * * * * * * * * ECM, extracellular matrix; EGF, epidermal growth factor; MMP, matrix metalloprotease; VEGF, vascular endothelial growth factor. * * There are a number of ways to target EGFR dysregulation. Antibodies against EGFR can act as receptor antagonists and prevent ligand binding. Antibodies against ligand can also block binding, and this approach may be useful when 1 ligand binds several receptors. Using a small molecule that specifically targets and either reversibly or irreversibly inhibits the tyrosine kinase activity is an approach that can block all EGFRs, including those with mutated or deleted extracellular domains. Conjugates of a ligand and a cytotoxic agent or an antibody and a cytotoxic agent is another approach that can have the advantage of killing the cell after internalization, in addition to inhibiting tyrosine kinase activity. EGFR, epidermal growth factor receptor; TK, tyrosine kinase. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. 2000;59:753-767. * ECOG, Eastern Cooperative Oncology Group; NCI, National Cancer Institute. * CR, complete response; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; PD, progressive disease; PR, partial response; SD, stable disease. * CI, confidence interval; HR, hazard ratio; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group. * CI, confidence interval; HR, hazard ratio; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; PS, performance status. * EGFR, epidermal growth factor receptor; Gr, grade; HR, hazard ratio; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group. * EGFR, epidermal growth factor receptor; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group. * EGFR, epidermal growth factor receptor. * * PS, performance status; SWOG, Southwest Oncology Group. Philip PA, et al. ASCO 2007. Abstract LBA4509. 文献更新：Philip PA, et